116 related articles for article (PubMed ID: 15515419)
1. The assessment of vegetative and functional symptoms in fibromyalgia patients: the tropisetron experience.
Kohnen R; Färber L; Späth M
Scand J Rheumatol Suppl; 2004; 119():67-71. PubMed ID: 15515419
[TBL] [Abstract][Full Text] [Related]
2. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain.
Haus U; Varga B; Stratz T; Späth M; Müller W
Scand J Rheumatol Suppl; 2000; 113():55-8. PubMed ID: 11028833
[TBL] [Abstract][Full Text] [Related]
3. Fibromyalgia treatment with intravenous tropisetron administration.
Stratz T; Färber L; Varga B; Baumgartner C; Haus U; Müller W
Drugs Exp Clin Res; 2001; 27(3):113-8. PubMed ID: 11447769
[TBL] [Abstract][Full Text] [Related]
4. Results of the intravenous administration of tropisetron in fibromyalgia patients.
Müller W; Stratz T
Scand J Rheumatol Suppl; 2000; 113():59-62. PubMed ID: 11028834
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group.
Färber L; Stratz T; Brückle W; Späth M; Pongratz D; Lautenschläger J; Kötter I; Zöller B; Peter HH; Neeck G; Alten R; Müller W
Scand J Rheumatol Suppl; 2000; 113():49-54. PubMed ID: 11028832
[TBL] [Abstract][Full Text] [Related]
6. Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients.
Färber L; Stratz TH; Brückle W; Späth M; Pongratz D; Lautenschläger J; Kötter I; Zöller B; Peter HH; Neeck G; Welzel D; Müller W;
Int J Clin Pharmacol Res; 2001; 21(1):1-13. PubMed ID: 11708570
[TBL] [Abstract][Full Text] [Related]
7. Treatment of fibromyalgia with tropisetron, a 5HT3 serotonin antagonist: a pilot study.
Papadopoulos IA; Georgiou PE; Katsimbri PP; Drosos AA
Clin Rheumatol; 2000; 19(1):6-8. PubMed ID: 10752491
[TBL] [Abstract][Full Text] [Related]
8. The 5-HT3 blockers in the treatment of the primary fibromyalgia syndrome: a 10-day open study with Tropisetron at a low dose.
Samborski W; Stratz T; Lacki JK; Klama K; Mennet P; Müller W
Mater Med Pol; 1996; 28(1):17-9. PubMed ID: 9088121
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia.
Späth M; Stratz T; Neeck G; Kötter I; Hammel B; Amberger CC; Haus U; Färber L; Pongratz D; Müller W
Scand J Rheumatol; 2004; 33(4):267-70. PubMed ID: 15370724
[TBL] [Abstract][Full Text] [Related]
10. 5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome.
Seidel MF; Weinreich GF; Stratz T; Müller W
Rheumatol Int; 2007 Sep; 27(11):1025-30. PubMed ID: 17634903
[TBL] [Abstract][Full Text] [Related]
11. Effect of tropisetron on circulating catecholamines and other putative biochemical markers in serum of patients with fibromyalgia.
Höcherl K; Färber L; Ladenburger S; Vosshage D; Stratz T; Müller W; Grobecker H
Scand J Rheumatol Suppl; 2000; 113():46-8. PubMed ID: 11028831
[TBL] [Abstract][Full Text] [Related]
12. Treatment of fibromyalgia with tropisetron--dose and efficacy correlations.
Späth M; Stratz T; Färber L; Haus U; Pongratz D
Scand J Rheumatol Suppl; 2004; 119():63-6. PubMed ID: 15515418
[TBL] [Abstract][Full Text] [Related]
13. [Pain modification by the 5-HT3 receptor antagonist tropisetron in secondary fibromyalgias].
Stratz T; Müller W
Fortschr Med Orig; 2002; 120(1):17-20. PubMed ID: 14518353
[TBL] [Abstract][Full Text] [Related]
14. [Therapy of generalized tendomyopathy (fibromyalgia) caused by blocking 5-HT3 receptors].
Stratz T; Schochat T; Hrycaj P; Lacki J; Mennet P; Färber L; Schweiger C; Müller W
Z Rheumatol; 1994; 53(6):335-8. PubMed ID: 7871905
[TBL] [Abstract][Full Text] [Related]
15. Do cytochrome enzymes influence the therapeutic effect of tropisetron in fibromyalgia?
Stratz T; Kees F; Müller W
Drugs Exp Clin Res; 2003; 29(2):91-4. PubMed ID: 12951840
[TBL] [Abstract][Full Text] [Related]
16. Intravenous treatment of fibromyalgia with the 5-HT3 receptor antagonist tropisetron in a rheumatological practice.
Tolk J; Kohnen R; Müller W
Scand J Rheumatol Suppl; 2004; 119():72-5. PubMed ID: 15515420
[TBL] [Abstract][Full Text] [Related]
17. A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder.
Lecrubier Y; Puech AJ; Azcona A; Bailey PE; Lataste X
Psychopharmacology (Berl); 1993; 112(1):129-33. PubMed ID: 7871001
[TBL] [Abstract][Full Text] [Related]
18. Effects of low power laser and low dose amitriptyline therapy on clinical symptoms and quality of life in fibromyalgia: a single-blind, placebo-controlled trial.
Gür A; Karakoc M; Nas K; Cevik R; Sarac J; Ataoglu S
Rheumatol Int; 2002 Sep; 22(5):188-93. PubMed ID: 12215864
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of patient-rated stiffness associated with fibromyalgia: a post-hoc analysis of 4 pooled, randomized clinical trials of duloxetine.
Bennett R; Russell IJ; Choy E; Spaeth M; Mease P; Kajdasz D; Walker D; Wang F; Chappell A
Clin Ther; 2012 Apr; 34(4):824-37. PubMed ID: 22421576
[TBL] [Abstract][Full Text] [Related]
20. [5-HT3 receptor antagonists as a new therapeutic principle in rheumatology?].
Pongratz D
Z Rheumatol; 2001 Feb; 60(1):47-8. PubMed ID: 11263014
[No Abstract] [Full Text] [Related]
[Next] [New Search]
